Fig. 5

Decision curve analysis of the nomogram and AJCC tumor staging for the cancer-specific survival prediction of combined hepatocellular-cholangiocarcinoma: (a–c) 1-, 3- and 5-year CSS benefits based on the training cohorts. (d–f) 1-, 3- and 5-year CSS benefits based on the validation cohorts.